Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3549492 in Healthy Participants With Overweight or Obesity
NCT07232732Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of naperiglipron in obesity (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration at 10 weeks. Started Oct 2025; status: completed.
02
Drugs
naperiglipron
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07232732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07232732.